))
Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech
Manage episode 501702927 series 3571902
A new head at MHRA, a streamlined government life sciences strategy, and a more sophisticated innovation ecosystem have Annalisa Jenkins optimistic about the future of U.K. biotech — and its potential to carve out a stronger global role.
On The BioCentury Show, Annalisa Jenkins, chair of Gemma Biotherapeutics, discussed the evolving landscape of biotech in the U.K. and the critical hurdles it faces as it implements the latest strategy. Jenkins, who was president and CEO of Dimension Therapeutics, is a committee member on the Science Board to FDA, a board member of Genomics England and Faster Cures, and chair of the court at the London School of Hygiene and Tropical Medicine.
View full story: https://www.biocentury.com/article/656787
#UKBiotech #MHRA #BiotechStrategy #GrowthCapital #RegulatoryScience #TalentAttraction
00:00 - Introduction
02:52 - State of U.K. Biotech
13:15 - Improving U.K.’s Path to Clinic
18:50 - What’s Next for MHRA
24:53 - Changes at FDA
29:58 - Working with China
Chapters
1. Introduction (00:00:00)
2. State of U.K. Biotech (00:02:52)
3. Improving U.K.’s Path to Clinic (00:13:15)
4. What’s Next for MHRA (00:18:50)
5. Changes at FDA (00:24:53)
6. Working with China (00:29:58)
43 episodes
Share
